{
    "root": "f9a32cbb-4453-4b49-8f93-fcb2a0e35753",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CAPRELSA",
    "value": "20250521",
    "ingredients": [
        {
            "name": "VANDETANIB",
            "code": "YO460OQ37K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49960"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 300",
            "code": "5655G9Y8AQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ],
    "indications": {
        "text": "caprelsa indicated treatment symptomatic progressive medullary thyroid cancer patients unresectable locally advanced metastatic disease . caprelsa patients indolent , asymptomatic slowly progressing disease careful consideration treatment related risks caprelsa .",
        "doid_entities": [
            {
                "text": "thyroid cancer (DOID:1781)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1781"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose caprelsa 300 mg taken orally daily disease progression unacceptable toxicity occurs . caprelsa may taken without food . take missed dose within 12 hours next dose . crush caprelsa tablets . tablets dispersed 2 ounces water stirring approximately 10 minutes ( completely dissolve ) . liquids dispersion . swallow immediately dispersion . mix remaining residue 4 additional ounces water swallow . dispersion also administered nasogastric gastrostomy tubes .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "100 mg tablets available bottles containing 30 tablets ( ndc 58468-7820-3 ) . 300 mg tablets available bottles containing 30 tablets ( ndc 58468-7840-3 ) .",
    "adverseReactions": "patients congenital long qt syndrome [ boxed warning ] .",
    "indications_original": "CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.\n                  Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.",
    "contraindications_original": "The recommended dose of CAPRELSA is 300 mg taken orally once daily until disease progression or unacceptable toxicity occurs.\n                  CAPRELSA may be taken with or without food.\n                  Do not take a missed dose within 12 hours of the next dose.\n                  Do not crush CAPRELSA tablets. The tablets can be dispersed in 2 ounces of water by stirring for approximately 10 minutes (will not completely dissolve). Do not use other liquids for dispersion. Swallow immediately after dispersion. Mix any remaining residue with 4 additional ounces of water and swallow.  \n                  The dispersion can also be administered through nasogastric or gastrostomy tubes.",
    "warningsAndPrecautions_original": "100 mg Tablets available in bottles containing 30 tablets (NDC 58468-7820-3).\n                  \n                     300 mg Tablets available in bottles containing 30 tablets (NDC 58468-7840-3).",
    "adverseReactions_original": "Do not use in patients with congenital long QT syndrome [see Boxed Warning].",
    "drug": [
        {
            "name": "CAPRELSA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49960"
        }
    ]
}